Increased 5‐HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations

Huot, Philippe, Johnston, Tom H., Darr, Tayyeba, Hazrati, Lili‐Naz, Visanji, Naomi P., Pires, Donna, Brotchie, Jonathan M., Fox, Susan H.·2010·Movement Disorders
DOI 10.1002/mds.23083

Cited by (153)

Items 101–153 of 153

  1. Vision loss and hallucinations: perspectives from neurology and ophthalmology
    Ali G. Hamedani · 2020 · Current Opinion in Neurology
  2. Visual mismatch negativity in Parkinson's psychosis and potential for testing treatment mechanisms
    Vignando, Miriam, ffytche, Dominic, Mazibuko, Ndabezinhle, Palma, Giulio, Montagnese, Marcella, Dave, Sonali, Nutt, David J, Gabay, Anthony S, Tai, Yen F, Batzu, Lucia et al. · 2024 · Brain Communications
  3. Management of Parkinson’s disease psychosis: first-line antipsychotic selection and rationale for continuing, combining, or switching
    Stuart Isaacson, Henry A. Nasrallah, Rajesh Pahwa, Gustavo Alva, Daniel E. Kremens, Stephen M. Stahl · 2025 · Expert Opinion on Pharmacotherapy
  4. Connectome-based brain fingerprints predict early cognitive decline in Parkinson’s patients with minor hallucinations
    Stampacchia, Sara, Bernasconi, Fosco, Van De Ville, Dimitri, Amico, Enrico, Pagonabarraga, Javier, Kulisevsky, Jaime, Blanke, Olaf · 2025
  5. Cross-Species Evidence for Psilocin-Induced Visual Distortions: Apparent Motion Is Perceived by Both Humans and Rats
    Čestmír Vejmola, Klára Šíchová, Kateřina Syrová, Lucie Janečková, Vlastimil Koudelka, Michael Tesař, Marek Nikolič, Michaela Viktorinová, Filip Tylš, Jakub Korčák et al. · 2025 · Biological Psychiatry Global Open Science
  6. Serotonin syndrome caused by escitalopram in Parkinson’s disease psychosis: a case report
    Shanmei Wang, Linghe Qiu, Qin Zhou, Caixia Chen, Jianhong Wu · 2024 · BMC Geriatrics
  7. Fatigue is associated with the onset of hallucinations in patients with Parkinson's disease: A 3-year prospective study
    Masanori Ikeda, Hiroshi Kataoka, Satoshi Ueno · 2016 · eNeurologicalSci
  8. Effect of the mGlu4 positive allosteric modulator ADX-88178 on parkinsonism, psychosis-like behaviours and dyskinesia in the MPTP-lesioned marmoset
    Imane Frouni, Cynthia Kwan, Dominique Bédard, Woojin Kang, Adjia Hamadjida, Stephen G. Nuara, Jim C. Gourdon, Philippe Huot · 2023 · Psychopharmacology
  9. Additive effects of mGluR2 positive allosteric modulation, mGluR2 orthosteric stimulation and 5-HT2AR antagonism on dyskinesia and psychosis-like behaviours in the MPTP-lesioned marmoset
    Stephen G. Nuara, Jim C. Gourdon, Shawn P. Maddaford, Philippe Huot · 2021 · Naunyn-Schmiedeberg s Archives of Pharmacology
  10. Psychosis in Parkinson’s Disease and Current Management Trends- an Updated Review of Literature
    Rajib Dutta · 2023 · Journal of Neuroscience and Neurological Disorders
  11. Breathing new life into neurotoxic-based monkey models of Parkinson's disease to study the complex biological interplay between serotonin and dopamine
    Véronique Sgambato · 2020 · Progress in brain research
  12. Visual Hallucinations in Serotonergic Psychedelics and Lewy Body Diseases
    Nathan H. Heller, Frederick Streeter Barrett, Tobias Buchborn, Daniel Collerton, David Dupuis, Adam L. Halberstadt, Renaud Jardri, Tehseen N. Noorani, Katrin H. Preller, John‐Paul Taylor et al. · 2025 · Schizophrenia Bulletin
  13. The Emerging Role of Pimavanserin in the Management of Parkinson’s Disease Psychosis
    Neal S. Hermanowicz, Gustavo Alva, Fernando Pagán, Alberto Javier Espay, Amita Patel, Katya Cruz Madrid, Daniel E. Kremens, Jim Kenney, Sheila M. Arquette, Gary J. Tereso et al. · 2017 · Journal of Managed Care & Specialty Pharmacy
  14. Positive allosteric mGluR2 modulation with BINA alleviates dyskinesia and psychosis-like behaviours in the MPTP-lesioned marmoset
    Woojin Kang, Imane Frouni, Dominique Bédard, Cynthia Kwan, Adjia Hamadjida, Stephen G. Nuara, Jim C. Gourdon, Philippe Huot · 2024 · Naunyn-Schmiedeberg s Archives of Pharmacology
  15. Association of the number of minor hallucinations and well-structured visual hallucinations in Parkinson’s disease
    Hai‐Ying Zhang, Yang Zhao, Yi Chen, Yuanyuan Feng, Bo Shen, Shuangshuang Dong, Jun Zhu, Xu Jiang, Dongfeng Li, Yaning Chen et al. · 2025 · npj Parkinson s Disease
  16. Sleep Paralysis: A Brief Overview of the Intersections of Neurophysiology and Culture
    Cyle Johnson · 2023 · American Journal of Psychiatry Residents Journal
  17. Global research trends and hotspots in Parkinson’s disease psychosis: a 25-year bibliometric and visual analysis
    Jianhong Wu, Xin Jin, Weiming Xie, Liang Liu, Fei Wang, Ling Zhu, Yuan Shen, Linghe Qiu · 2024 · Frontiers in Aging Neuroscience
  18. How Layer-Specific fMRI Can Contribute to Understanding Perceptual Disturbances Across Psychiatric Disorders
    Joost Haarsma, Peter Kok · 2025 · Current topics in behavioral neurosciences
  19. Psychosis
    Eric Molho, Stewart Alan Factor · 2012 · Humana Press eBooks
  20. Therapies under investigation for treating Parkinson's disease psychosis
    Niem Tu Huynh, Philippe Huot · 2014 · Clinical Investigation
  21. Crosstalk Between 5-HT2A and mGlu2 Receptors: Implications in Schizophrenia and Its Treatment
    José L. Moreno, Javier González‐Maeso · 2018 · Springer eBooks
  22. Beyond Dopamine
    Dennis Velakoulis, Ramon Mocellin, Andrew H. Evans, Mark Walterfang · 2016 · Elsevier eBooks
  23. Exploring Psilocybin as a Tool for Studying Parkinsonism-Related Psychosis: A Narrative Review Supplemented with a Computational Approach
    Asja Čampara, Dženan Kovačić · 2024 · World Congress on Medical Physics and Biomedical Engineering, September 7 - 12, 2009, Munich, Germany
  24. Effect of the mGlu2 receptor positive allosteric modulator AZD8529 on L-DOPA-induced dyskinesia and psychosis-like behaviours in the parkinsonian marmoset
    Judy Shaqfah, Dominique Bédard, Stephen G. Nuara, Jim C. Gourdon, Adjia Hamadjida, Fleur Gaudette, Francis Beaudry, Philippe Huot · 2025 · European Journal of Pharmacology
  25. Patient-specific functional networks track early cognitive alterations and minor hallucinations in Parkinson’s disease
    Sara Stampacchia, Fosco Bernasconi, Dimitri Van De Ville, Enrico Amico, Lada Kohoutová, John‐Paul Taylor, Alan J. Thomas, Javier Pagonabarraga, Jaime Kulisevsky, Olaf Blanke · 2026 · Nature Mental Health
  26. Depression in neurodegenerative disease: neurobiological mechanisms and emerging treatments
    Harry Costello, Suzanne Reeves, Paul Glue, Allan Hunter Young, Robert J. Howard · 2026 · Molecular Psychiatry
  27. Pharmacotherapy of Psychosis in Parkinson’s Disease
    Cynthia Kwan, Imane Frouni, Philippe Huot · 2020 · Springer eBooks
  28. Pharmacotherapy of Psychosis in Parkinson’s Disease
    Cynthia Kwan, Imane Frouni, Philippe Huot · 2022 · Springer eBooks
  29. Ondansetron for the treatment of Parkinson’s disease psychosis: Rationale and literature review
    Jaslovleen Kaur, Abhishek Lenka, J. Isaacson, Stuart Isaacson · 2023 · Annals of Movement Disorders
  30. General aspects
    Dag Aarsland, Jeffrey L. Cummings, Daniel Weintraub, К. Ray Chaudhuri · 2013 · Cambridge University Press eBooks
  31. Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease: An Open-Label Pilot Trial
    Ellen Bradley, Kimberly Sakai, Gisele Fernandes‐Osterhold, Balázs Szigeti, Connie Ludwig, Jill L. Ostrem, Caroline M. Tanner, Meredith Bock, Katiah Llerena, Patrick R. Finley et al. · 2024 · SSRN Electronic Journal
  32. Deviations in effective connectivity explain different hallucination subtypes in Parkinson's disease psychosis
    Vignando, Miriam, Ffytche, Dominic, Mazibuko, Ndabezinhle, Palma, Giulio, Bhat, Anjali, Montagnese, Marcella, Dave, Sonali, Tai, Yen F., Batzu, Lucia, Leta, Valentina et al. · 2026 · Nature Mental Health
  33. The Efficacy of Yokukansan to Treat the Behavioral and Psychological Symptoms of Dementia Patients
    Yoshihito Hayashi, Yasushi Ishida · 2012 · Kyushu Neuropsychiatry
  34. Tryptophan Metabolism in Parkinson’s Disease: Future Therapeutic Possibilities
    Zsófia Majláth, László Vécsei · 2013 · Royal Society of Chemistry eBooks
  35. Parkinson’s disease: pathology, anatomy, and behavior
    Daniel J. Burdick, James B. Leverenz · 2013 · Cambridge University Press eBooks
  36. Neuropsychiatric Symptoms in the Course of Parkinson’s Disease
    Kasia Gustaw Rothenberg · 2020 · Biomedical Journal of Scientific & Technical Research
  37. An Adaptive Network Model for Sleep Paralysis: The Risk Factors and Working Mechanisms
    Willem D. Huijzer, J. Treur · 2021 · Software Engineering Application in Informatics
  38. Pharmacodynamics
    Carlos H. Rojas‐Fernandez · 2016 · Springer eBooks
  39. Drug-Induced Non-Motor Symptoms in Parkinson’s Disease
    Camila Aquino · 2022 · Cambridge University Press eBooks
  40. Neuropsychiatric (Behavioral) Symptoms in Parkinson’s Disease
    Kasia Gustaw Rothenberg · 2022 · Cambridge University Press eBooks
  41. Motor and non-motor effects of apomorphine infusion
    Robbert W. K. Borgemeester · 2022
  42. Role of Pimavanserin Treatment-Continuity on Discharge From Long-term Care: Assessing the Quality of Antipsychotic Medication Review
    Krithika Rajagopalan, Damian May, Chad Worz, Stephanie H. Hernandez, Dilesh Doshi · 2022 · The Senior Care Pharmacist
  43. Diagnosis and treatment of hallucinations in elderly palliative care patients with Parkinson’s disease
    Karolina Ochyra, Zbigniew Żylicz · 2023 · Palliative Medicine in Practice
  44. Treatment Tactics for Psychosis in Parkinson’s Disease: A Literature Review
    Daiva Milmantienė · 2024 · Neurologijos seminarai
  45. Effects of ayahuasca in preclinical studies with animals: a systematic review
    André Walsh-Monteiro, Sílvio Morato, Fabio Aléxis Rincón Uribe, Amauri Gouvêia, Janari da Silva Pedroso · 2025 · Brazilian Journal of Medical and Biological Research
  46. Role of the raphe-serotonin system in Parkinson's disease: Compensatory versus maladaptive plasticity
    Ashley Galfano, Kuei Tseng, Fredric Manfredsson, Christopher Bishop · 2025 · Handbook of behavioral neuroscience
  47. Network dynamic of basal ganglia circuits in normal and parkinsonian conditions
    Lise Guilhemsang · 2022
  48. Dopamine and serotonin: overview of the functions and function disorders, leading to neurodegeneration
    Hrant Avanesyan, Marine A. Parsadanyan, Mariam A. Shahinyan, Локян Арсен Багдасарович, Marieta S. Mikaelyan, Svetlana V. Grigoryan, P. O. Vardevanyan · 2025 · Neurophysiology
  49. The Influence of 5-HT2 Receptors on Multimodal Sensorimotor Gating and Hallucination-Like Behavior in Hemiparkinsonian Rats
    Shruti Venkatesh, Haley Prisinzano, Natalie Lipari, Jacleen Nardiello, Carla Budrow, Grace McManus, Emily Wheelis, Fredric P. Manfredsson, Kuei Yuan Tseng, Ashley M. Stokes et al. · 2026 · Research Square
  50. Cellular mechanisms of serotonergic psychedelics - apical hypercontextualisation
    Kristjan Kaup, Javier Hidalgo Jiménez, Jaan Aru · 2026 · Neuroscience & Biobehavioral Reviews
  51. Inflammation and neuropsychiatric symptoms in Parkinson's disease: a genetic association
    Alexandra Ribeiro Gonçalves, Alexandre Mendes, Joana Damásio, Nuno Vila‐Chã, Daniela Boleixa, Cristina Santos, Bárbara Leal, Sara Cavaco · 2026 · Frontiers in Aging Neuroscience
  52. Reduced volume of neuromodulatory brainstem nuclei is associated with early hallucination-related vulnerability in Parkinson’s disease
    Gabriella Monopoli, Federica Tomaiuolo, Carlo Sestieri, Miriam Punzi, Simone Marino, Francesco Gambi, Mauro Gianni Perrucci, Antonio Ferretti, Stefano Luca Sensi, Stefano Delli Pizzi · 2026 · Brain Communications
  53. Transdiagnostic mechanisms underlying non-affective psychosis: A role for hippocampal networks?
    Claire Kaplan, Kate Perepezko, Gregory M. Pontone, Arnold Bakker · 2026 · American Journal of Geriatric Psychiatry